TargetMol

Perindopril erbumine

Product Code:
 
TAR-T1484L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1484L-100mg100mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1484L-200mg200mg£133.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Perindopril Erbumine is the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, perindopril erbumine is converted to its active form perindoprilat, inhibiting ACE and the conversion of angiotensin I to angiotensin II; consequently, angiotensin II-mediated vasoconstriction and angiotensin II-stimulated aldosterone secretion from the adrenal cortex are inhibited and diuresis and natriuresis ensue.
CAS:
107133-36-8
Formula:
C23H43N3O5
Molecular Weight:
441.613
Pathway:
Apoptosis; Immunology/Inflammation; Endocrinology/Hormones
Purity:
0.998
SMILES:
CC(C)(C)N.[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Target:
Apoptosis; RAAS; MRP

References

1. Ceconi C, et al. Eur J Pharmacol, 2007, 577(1-3), 1-6. 2. Zou K, et al. J Biol Chem, 2009, 284(46), 31914-31920. 3. Yasumatsu R, et al. J Cancer Res Clin Oncol, 2004, 130(10), 567-573. 4. Yoshiji H, et al. Clin Cancer Res, 2001, 7(4), 1073-1078. 5. Ceconi C, et al. Cardiovasc Drugs Ther, 2007, 21(6), 423-429.